argenx (ARGX) News
NASDAQ: ARGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
825.03+6.40 (+0.78%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 825.03 0.00%
ARGX news summary
We found 46 recent headlines mentioning argenx (ARGX): 15 in the past week and 21 in the past 30 days, most often from Nasdaq, Seeking Alpha, GlobeNewswire. For price context, ARGX is up 0.78% at $825.03. The most recent story, "Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest argenx headlines
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) - This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.NasdaqABBV, ALVO, ARGX, BBIO
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.NasdaqARGX, ALNY, AMRN, ALDX
- argenx: The Sjögren's Selloff Looks OverdoneSeeking Alpha
- ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Studyargenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.NasdaqARGX, ALNY, CRSP
- argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation. NEW YORK, Oct. 8, 2026…PR Newswire
- HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeHalozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.NasdaqHALO, JNJ, MRK, ARGX
- Argenx Reports Mixed Pipeline Update With Positive Celiac Data; Ends Sjögren's Phase 3 Study(RTTNews) - argenx SE (ARGX), a global immunology company, provided updates on two clinical programs, reporting positive Phase 2 results for FB102 in celiac disease while discontinuing the Phase 3…NasdaqARGX, ET
- Argenx's Celiac Disease Phase 2 Study Meets Primary Endpoint; Discontinues Sjögren's UNITY Trial(RTTNews) - argenx SE (ARGX), an immunology company, on Thursday reported positive Phase 2 results for FB102 in celiac disease and separately announced that it will discontinue the Phase 3 UNITY…Nasdaq
- Argenx To Discontinue Phase 3 UNITY Study Of Efgartigimod In Sjgren's Disease(RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease. Following interim analysis, an…NasdaqARGX, BRK.A
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac DiseaseOctober 8, 2026, 7:00 AM CETGlobeNewswire
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's DiseaseOctober 8, 2026, 7:00 AM CETGlobeNewswire
- HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXHalozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.NasdaqHALO, JNJ, ARGX, HOWL
- Halozyme, Argenx Expand ENHANZE Collaboration With Two Additional Targets(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced an expansion of its global collaboration with argenx SE(ARGX), granting the company exclusive access to its ENHANZE drug-delivery technology…NasdaqARGX, HALO
- BMY or ARGX: Which Is the Better Value Stock Right Now?BMY vs. ARGX: Which Stock Is the Better Value Option?NasdaqBMY, ARGX
- 10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?Key PointsWall Street is overwhelmingly bullish about Argenx.NasdaqARGX, C, MS, WFC
- iShares Biotechnology ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an…NasdaqIBB, REGN, NTRA, ARGX
- Argenx To Present New VYVGART Data Across Autoimmune Neuromuscular Disorder At AANEM & MGF Session(RTTNews) - On Tuesday, Argenx SE (ARGX) announced that it will present new clinical, long-term and real-world data for VYVGART (efgartigimod) across Myasthenia gravis and Chronic inflammatory…Nasdaq
- Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 MonthsKey PointsArgenx's Vyvgart franchise enjoys strong sales momentum.NasdaqARGX, WFC, UBS
- 2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.Key PointsWells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price.NasdaqARGX, WFC, UBS
- BMY vs. ARGX: Which Stock Is the Better Value Option?BMY vs. ARGX: Which Stock Is the Better Value Option?NasdaqBMY, ARGX
- argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaARGX, MS
- Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?Key PointsArgenx's top and bottom lines are growing robustly.NasdaqARGX, SPGI, HALO
- Argenx upgraded at UBS; sees $20B peak sales in VyvgartSeeking Alpha
- Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger StoryKey PointsArgenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis.NasdaqARGX, SPGI
- Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT(RTTNews) - The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.NasdaqARGX, BOLD, CORT, ELOX
- HALO Stock Rises 36% in a Month: Here's What You Should KnowHalozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.NasdaqHALO, JNJ, RGEN, ARGX
- Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) - This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts.…NasdaqALIT, ARGX, AZN, BMRN
- argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis - SlideshowSeeking Alpha
- ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Upargenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.NasdaqARGX, ACIU, AMRX, PGEN
- argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis TranscriptSeeking Alpha
- argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - SlideshowSeeking Alpha
- argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To GoSeeking Alpha
- Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 BillionSeeking Alpha
- argenx SE (ARGX) M&A Call TranscriptSeeking Alpha
- argenx To Acquire Forte Biosciences: What Investors Should KnowSeeking Alpha
- argenx: Vyvgart Is Taking Off (Rating Upgrade)Seeking Alpha
- argenx SE (ARGX) Q2 2026 Earnings Call TranscriptSeeking Alpha
- argenx SE 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis TranscriptSeeking Alpha
- argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis - SlideshowSeeking Alpha
- argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking AlphaARGX, GS
- argenx: The FcRn Franchise Is Becoming An Autoimmune Operating SystemSeeking Alpha
- argenx SE 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaARGX, BAC
- argenx SE (ARGX) Q1 2026 Earnings Call TranscriptSeeking Alpha
- argenx SE: Excellent Company, Premium ValuationSeeking Alpha